Premium
Prostatic Cancer: Treatment with Long‐acting LHRH Analogue
Author(s) -
WILLIAMS GORDON,
ALLEN JANET M.,
O'SHEA J. P.,
MASHITER K.,
DOBLE A.,
BLOOM S. R.
Publication year - 1983
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1983.tb03417.x
Subject(s) - medicine , agonist , hormone , prostate cancer , hormone therapy , oncology , disease , cancer , prostate , prostate carcinoma , endocrinology , urology , receptor , breast cancer
Summary— Fifteen patients with advanced carcinoma of the prostate were treated with a luteinising hormone releasing hormone agonist ICI 118 630. Three of 5 patients who had failed conventional hormone therapy have had a marked alleviation of bone pain, though no objective evidence of disease regression. Nine of 10 patients previously untreated have shown objective evidence of disease response. This drug appears to have advantages over conventional hormone therapy.